BACKGROUND: Fragile X-associated tremor/ataxia syndrome (FXTAS), which occurs in some premutation carriers of the fragile X mental retardation 1 (FMR1) gene, is a neurodegenerative disorder characterized by action tremor, gait ataxia, and impaired executive cognitive functioning. OBJECTIVE: To evaluate the nature and severity of functional limitations among male carriers of the fragile X premutation, both with and without FXTAS. METHODS: Forty-two subjects with FXTAS and 24 asymptomatic premutation carriers were compared to 32 control subjects on measures of physical functioning, activities of daily living (ADLs; e.g. eating, bathing), and instrumental activities of daily living (IADLs; e.g. shopping, managing medications). Ordinary least squares regression, controlling for age, education, medical comorbidity, and pain, was used to examine group differences in physical and functional performance. RESULTS: Men with FXTAS performed significantly worse than control subjects on all dependent measures, showing greater limitations in physical functioning, as well as ADL and IADL performance (p < 0.05). Subsequent analyses suggested that physical and functional impairments among men with FXTAS result largely from deficits in motor and executive functioning and that CGG repeat length is associated with functional impairment. Asymptomatic carriers of the fragile X premutation performed similarly to control subjects on all measures. CONCLUSIONS: This study provides the first comprehensive evaluation of functional status among male premutation carriers. Although carriers without FXTAS performed similarly to control subjects, men with FXTAS showed evidence of significant physical and functional impairment, which appears to result largely from motor and executive deficits characteristic of the syndrome. Copyright (c) 2009 John Wiley & Sons, Ltd.
BACKGROUND:Fragile X-associated tremor/ataxia syndrome (FXTAS), which occurs in some premutation carriers of the fragile X mental retardation 1 (FMR1) gene, is a neurodegenerative disorder characterized by action tremor, gait ataxia, and impaired executive cognitive functioning. OBJECTIVE: To evaluate the nature and severity of functional limitations among male carriers of the fragile X premutation, both with and without FXTAS. METHODS: Forty-two subjects with FXTAS and 24 asymptomatic premutation carriers were compared to 32 control subjects on measures of physical functioning, activities of daily living (ADLs; e.g. eating, bathing), and instrumental activities of daily living (IADLs; e.g. shopping, managing medications). Ordinary least squares regression, controlling for age, education, medical comorbidity, and pain, was used to examine group differences in physical and functional performance. RESULTS:Men with FXTAS performed significantly worse than control subjects on all dependent measures, showing greater limitations in physical functioning, as well as ADL and IADL performance (p < 0.05). Subsequent analyses suggested that physical and functional impairments among men with FXTAS result largely from deficits in motor and executive functioning and that CGG repeat length is associated with functional impairment. Asymptomatic carriers of the fragile X premutation performed similarly to control subjects on all measures. CONCLUSIONS: This study provides the first comprehensive evaluation of functional status among male premutation carriers. Although carriers without FXTAS performed similarly to control subjects, men with FXTAS showed evidence of significant physical and functional impairment, which appears to result largely from motor and executive deficits characteristic of the syndrome. Copyright (c) 2009 John Wiley & Sons, Ltd.
Authors: Jim Grigsby; Angela G Brega; Sébastien Jacquemont; Danuta Z Loesch; Maureen A Leehey; Glenn K Goodrich; Randi J Hagerman; Jennifer Epstein; Rebecca Wilson; Jennifer B Cogswell; Tristan Jardini; Flora Tassone; Paul J Hagerman Journal: J Neurol Sci Date: 2006-06-15 Impact factor: 3.181
Authors: Jim Grigsby; Angela G Brega; Karen Engle; Maureen A Leehey; Randi J Hagerman; Flora Tassone; David Hessl; Paul J Hagerman; Jennifer B Cogswell; Rachael E Bennett; Kylee Cook; Deborah A Hall; Lanee S Bounds; Marsha J Paulich; Ann Reynolds Journal: Neuropsychology Date: 2008-01 Impact factor: 3.295
Authors: Elizabeth Berry-Kravis; Liane Abrams; Sarah M Coffey; Deborah A Hall; Claudia Greco; Louise W Gane; Jim Grigsby; James A Bourgeois; Brenda Finucane; Sebastien Jacquemont; James A Brunberg; Lin Zhang; Janet Lin; Flora Tassone; Paul J Hagerman; Randi J Hagerman; Maureen A Leehey Journal: Mov Disord Date: 2007-10-31 Impact factor: 10.338
Authors: Melissa S Y Thong; Mirjam A G Sprangers; Jeff A Sloan; Donald L Patrick; Ping Yang; Cornelis J F van Noorden Journal: Qual Life Res Date: 2014-11-12 Impact factor: 4.147
Authors: Dalyir I Pretto; John S Eid; Carolyn M Yrigollen; Hiu-Tung Tang; Erick W Loomis; Chris Raske; Blythe Durbin-Johnson; Paul J Hagerman; Flora Tassone Journal: J Med Genet Date: 2014-10-30 Impact factor: 6.318
Authors: Andreea L Seritan; Danh V Nguyen; Yi Mu; Flora Tassone; James A Bourgeois; Andrea Schneider; Jennifer B Cogswell; Kylee R Cook; Maureen A Leehey; Jim Grigsby; John M Olichney; Patrick E Adams; Wendi Legg; Lin Zhang; Paul J Hagerman; Randi J Hagerman Journal: J Clin Psychiatry Date: 2014-03 Impact factor: 4.384